According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “
A number of other analysts also recently commented on ANIP. BidaskClub upgraded Zai Lab from a buy rating to a strong-buy rating in a report on Friday, June 28th. ValuEngine upgraded Xylem from a hold rating to a buy rating in a report on Friday, June 21st. Canaccord Genuity downgraded Magellan Aerospace from a buy rating to a hold rating and dropped their price objective for the stock from C$21.00 to C$20.00 in a report on Monday, May 13th. Raymond James restated a buy rating on shares of Canadian Natural Resources in a report on Friday, May 10th. Finally, Cantor Fitzgerald restated a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a report on Thursday, May 9th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. ANI Pharmaceuticals has an average rating of Buy and a consensus target price of $84.50.
Shares of ANIP opened at $81.36 on Wednesday. The company has a fifty day simple moving average of $75.21. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The firm has a market cap of $962.23 million, a P/E ratio of 17.07 and a beta of 2.25. ANI Pharmaceuticals has a fifty-two week low of $36.92 and a fifty-two week high of $84.10.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.25. The company had revenue of $52.90 million during the quarter, compared to the consensus estimate of $50.57 million. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. ANI Pharmaceuticals’s revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.32 EPS. As a group, research analysts anticipate that ANI Pharmaceuticals will post 5.57 earnings per share for the current year.
In other news, insider Arthur Przybyl sold 30,000 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $70.07, for a total transaction of $2,102,100.00. Following the completion of the sale, the insider now directly owns 222,994 shares in the company, valued at approximately $15,625,189.58. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David Nash acquired 1,445 shares of the company’s stock in a transaction dated Friday, May 24th. The shares were purchased at an average price of $68.76 per share, with a total value of $99,358.20. Following the completion of the acquisition, the director now owns 5,236 shares in the company, valued at $360,027.36. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 50,911 shares of company stock valued at $3,585,114. Insiders own 24.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in ANIP. Global Alpha Capital Management Ltd. acquired a new stake in ANI Pharmaceuticals in the 1st quarter valued at $6,808,000. SG Americas Securities LLC increased its holdings in ANI Pharmaceuticals by 1,954.0% in the 1st quarter. SG Americas Securities LLC now owns 67,904 shares of the specialty pharmaceutical company’s stock valued at $4,790,000 after purchasing an additional 64,598 shares in the last quarter. Phocas Financial Corp. increased its holdings in ANI Pharmaceuticals by 33.7% in the 4th quarter. Phocas Financial Corp. now owns 129,476 shares of the specialty pharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 32,671 shares in the last quarter. Martingale Asset Management L P acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at $1,050,000. Finally, LSV Asset Management increased its holdings in ANI Pharmaceuticals by 28.0% in the 1st quarter. LSV Asset Management now owns 81,785 shares of the specialty pharmaceutical company’s stock valued at $5,769,000 after purchasing an additional 17,885 shares in the last quarter. Hedge funds and other institutional investors own 63.92% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.